AI FOR SCIENCE · ON THE RECORD
Potential Sciences
Runs gold-standard quantum chemistry (CCSD(T)) on GPUs, at what it says is a hundredth of the usual cost, to compute training data for atomistic models of how molecules bind and react, starting with small-molecule drug discovery for AI-first labs.
Full funding record →On the timeline →People filter →
Timeline
- 2026-11-05Potential Sciences, founded by Hatem Helal in Cambridge, comes out of stealth with an eight-figure seed backed by the UK's Sovereign AI fund and Twin
Path Ventures Capital - 2026-09-18The UK's £500m Sovereign AI fund is close to anchoring a round in drug-discovery start-up
Potential Sciences Capital
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Funding rounds tracked
- 2026-11-05Seed · eight-figure sum (capital and compute)confirmedWith UK Sovereign AI Fund, Twin Path Ventures, Nauta Capital, Odyssey, Portfolio Ventures, Blue Wire Capital, Rule30, Lightfield Equity, Patrick Collison, Chris Gibson (Recursion)
Each round links to its line on the funding record, with its source.
Also in Drug discovery on the funding board
The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.
- 2026-11-04Isomorphic LabsRound (unnamed) · $5BAlphabet's drug-design company, spun out of DeepMind to build on AlphaFold: it builds AI models to design drug candidates for its own pipeline and for pharma partners.
- 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
- 2026-10-29PerturbMindAngel and Angel+ · tens of millions of yuanBuilds AlphaCell, a model meant to predict how a cell's gene expression changes when a gene or a drug perturbs it, to help find disease mechanisms, new targets and new kinds of drugs; it plans to sell on-device service subscriptions and private deployments and to co-run drug programmes.
- 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
- 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
- 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.